Cetera's GrowthLine Program Recognized with 2025 BISA Technology Innovation Award
March 6, 2025 - 20:38
Cetera Financial Group has been honored with the prestigious 2025 Bank Insurance & Securities Association (BISA) Technology Innovation Award for its innovative GrowthLine Marketing Program. This recognition highlights Cetera's commitment to enhancing the financial advisory landscape through cutting-edge technology and strategic marketing initiatives.
The GrowthLine Program is designed to empower financial advisors by providing them with robust tools and resources to effectively engage clients and streamline their marketing efforts. This initiative not only enhances the client experience but also enables advisors to grow their practices in a highly competitive environment.
Cetera's focus on integrating technology with personalized service has set a new standard in the financial services industry. The award underscores the importance of innovation in meeting the evolving needs of clients and advisors alike. As the financial landscape continues to change, Cetera remains dedicated to fostering growth and success for its advisors through innovative solutions.
MORE NEWS
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...